Literature DB >> 28275963

Adverse Drug Event Causality Analysis (ADECA): A Process for Evaluating Evidence and Assigning Drugs to Risk Categories for Sudden Death.

Raymond L Woosley1,2, Klaus Romero3, Craig W Heise4, Tyler Gallo4, Jared Tate5, Raymond David Woosley6, Sophie Ward7.   

Abstract

Growing evidence indicates that many drugs have the ability to cause a potentially lethal cardiac arrhythmia, torsades de pointes (TdP). This necessitates the development of a compilation of drugs that have this potential toxicity. Such a list is helpful in identifying the etiology of TdP in patients taking multiple drugs and assists decision making by those caring for patients at high risk of TdP. The Arizona Center for Education and Research on Therapeutics (AZCERT) has developed a process to standardize the identification of drugs and place them in risk categories for their clinical ability to cause TdP and QT prolongation. AZCERT's Adverse Drug Event Causality Analysis (ADECA) utilizes 16 types of data drawn from four sources to compile an open-source knowledge base, QTdrugs, which is maintained on the CredibleMeds.org website. Because the evidence for most drugs is incomplete, the ADECA process is used to place drugs into one of three categories that represent different levels of certainty: known TdP risk, possible TdP risk, and conditional TdP risk. Each category has strict evidentiary requirements for clinical evidence of TdP and/or QT prolongation. These are described in this paper. Because evidence can evolve over time, the ADECA process includes the continuous gathering and analysis of newly emerging evidence to revise the lists. The QTdrugs lists have proven to be a valued, readily available, commercial influence-free resource for healthcare providers, patients, researchers, and authors of consensus guidelines for the safe use of medicines.

Entities:  

Mesh:

Year:  2017        PMID: 28275963     DOI: 10.1007/s40264-017-0519-0

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  40 in total

1.  Impact of clinical decision support preventing the use of QT-prolonging medications for patients at risk for torsade de pointes.

Authors:  Atsushi Sorita; J Martijn Bos; Bruce W Morlan; Robert F Tarrell; Michael J Ackerman; Pedro J Caraballo
Journal:  J Am Med Inform Assoc       Date:  2014-10-16       Impact factor: 4.497

2.  Cardiovascular safety of second-generation antihistamines.

Authors:  J T Barbey; M Anderson; G Ciprandi; A J Frew; M Morad; S G Priori; E Ongini; M B Affrime
Journal:  Am J Rhinol       Date:  1999 May-Jun

3.  Torsades de pointes induced by nonantiarrhythmic drugs.

Authors:  H T Tran
Journal:  Conn Med       Date:  1994-05

4.  Centers for education and research in therapeutics.

Authors:  R L Woosley
Journal:  Clin Pharmacol Ther       Date:  1994-03       Impact factor: 6.875

5.  Influence of opioid agonists on cardiac human ether-a-go-go-related gene K(+) currents.

Authors:  Alexander N Katchman; Kelly A McGroary; Michael J Kilborn; Craig A Kornick; Paolo L Manfredi; Raymond L Woosley; Steven N Ebert
Journal:  J Pharmacol Exp Ther       Date:  2002-11       Impact factor: 4.030

6.  Application of the bradford hill criteria to assess the causality of cisapride-induced arrhythmia: a model for assessing causal association in pharmacovigilance.

Authors:  Michael Perrio; Simon Voss; Saad A W Shakir
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

7.  QT prolongation and torsades de pointes among methadone users: reports to the FDA spontaneous reporting system.

Authors:  Ellen C Pearson; Raymond L Woosley
Journal:  Pharmacoepidemiol Drug Saf       Date:  2005-11       Impact factor: 2.890

8.  Pharmacovigilance in the 21st century: new systematic tools for an old problem.

Authors:  Ana Szarfman; Joseph M Tonning; P Murali Doraiswamy
Journal:  Pharmacotherapy       Date:  2004-09       Impact factor: 4.705

9.  Mechanism of the cardiotoxic actions of terfenadine.

Authors:  R L Woosley; Y Chen; J P Freiman; R A Gillis
Journal:  JAMA       Date:  1993 Mar 24-31       Impact factor: 56.272

10.  Systems analysis of adverse drug events. ADE Prevention Study Group.

Authors:  L L Leape; D W Bates; D J Cullen; J Cooper; H J Demonaco; T Gallivan; R Hallisey; J Ives; N Laird; G Laffel
Journal:  JAMA       Date:  1995-07-05       Impact factor: 56.272

View more
  9 in total

1.  Drug-Induced Arrhythmia: Bridging the Gap Between Pathophysiological Knowledge and Clinical Practice.

Authors:  Elisabetta Poluzzi; Emanuel Raschi; Igor Diemberger; Fabrizio De Ponti
Journal:  Drug Saf       Date:  2017-06       Impact factor: 5.606

2.  Association of QT-Prolonging Medications With Risk of Autopsy-Defined Causes of Sudden Death.

Authors:  Timothy F Simpson; James W Salazar; Eric Vittinghoff; Joanne Probert; Alan Iwahashi; Jeffrey E Olgin; Phillip Ursell; Amy Hart; Ellen Moffatt; Zian H Tseng
Journal:  JAMA Intern Med       Date:  2020-05-01       Impact factor: 21.873

3.  QTc prolongation during ciprofloxacin and fluconazole combination therapy: prevalence and associated risk factors.

Authors:  Florine A Berger; Nico Monadian; Natasja M S de Groot; Bart Santbergen; Heleen van der Sijs; Matthijs L Becker; Annoek E C Broers; Teun van Gelder; Patricia M L A van den Bemt
Journal:  Br J Clin Pharmacol       Date:  2017-12-06       Impact factor: 4.335

4.  Importance of Publishing Adverse Drug Reaction Case Reports: Promoting Public Health and Advancing Pharmacology and Therapeutics.

Authors:  Rashmi R Shah
Journal:  Drug Saf Case Rep       Date:  2017-09-20

5.  Complex versus simple models: ion-channel cardiac toxicity prediction.

Authors:  Hitesh B Mistry
Journal:  PeerJ       Date:  2018-02-05       Impact factor: 2.984

6.  The Risk of QTc-Interval Prolongation in Breast Cancer Patients Treated with Tamoxifen in Combination with Serotonin Reuptake Inhibitors.

Authors:  Koen G A M Hussaarts; Florine A Berger; Lisette Binkhorst; Esther Oomen-de Hoop; Roelof W F van Leeuwen; Robbert J van Alphen; Daniëlle Mathijssen-van Stein; Natasja M S de Groot; Ron H J Mathijssen; Teun van Gelder
Journal:  Pharm Res       Date:  2019-12-16       Impact factor: 4.200

7.  The use of a clinical decision support tool to assess the risk of QT drug-drug interactions in community pharmacies.

Authors:  Florine A Berger; Heleen van der Sijs; Teun van Gelder; Patricia M L A van den Bemt
Journal:  Ther Adv Drug Saf       Date:  2021-02-24

Review 8.  Comparative risk of cardiac arrhythmias associated with acetylcholinesterase inhibitors used in treatment of dementias - A narrative review.

Authors:  Yichang Huang; Mhd Wasem Alsabbagh
Journal:  Pharmacol Res Perspect       Date:  2020-08

9.  Use of Patient Health Records to Quantify Drug-Related Pro-arrhythmic Risk.

Authors:  Mark R Davies; Michael Martinec; Robert Walls; Roman Schwarz; Gary R Mirams; Ken Wang; Guido Steiner; Andy Surinach; Carlos Flores; Thierry Lavé; Thomas Singer; Liudmila Polonchuk
Journal:  Cell Rep Med       Date:  2020-08-25
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.